|
1
|
Traverse-Glehen A, Pittaluga S, Gaulard P,
Sorbara L, Alonso MA, Raffeld M and Jaffe ES: Mediastinal gray zone
lymphoma: The missing link between classic Hodgkin's lymphoma and
mediastinal large B-cell lymphoma. Am J Surg Pathol. 29:1411–1421.
2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pilichowska M, Pittaluga S, Ferry JA,
Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS,
Kritharis A, et al: Clinicopathologic consensus study of gray zone
lymphoma with features intermediate between DLBCL and classical HL.
Blood Adv. 1:2600–2609. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Evens AM, Kanakry JA, Sehn LH, Kritharis
A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Herna
dez-Ilizaliturri FJ, et al: Gray zone lymphoma with features
intermediate between classical Hodgkin lymphoma and diffuse large
B-cell lymphoma: Characteristics, outcomes, and prognostication
among a large multicenter cohort. Am J Hematol. 90:778–783.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kritharis A, Pilichowska M and Evens AM:
How I manage patients with grey zone lymphoma. Br J Haematol.
174:345–350. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Svoboda J, Bair SM, Landsburg DJ, Nasta
SD, Nagle SJ, Barta SK, Khan N, Filicko-O'Hara J, Gaballa S,
Strelec L, et al: Brentuximab vedotin in combination with
rituximab, cyclophosphamide, doxorubicin, and prednisone as
frontline treatment for patients with CD30-positive B-cell
lymphomas. Haematologica: May 15, 2020 (Epub ahead of print).
|
|
6
|
Younes A, Gopal AK, Smith SE, Ansell SM,
Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de
Vos S, et al: Results of a pivotal phase II study of brentuximab
vedotin for patients with relapsed or refractory Hodgkin's
lymphoma. J Clin Oncol. 30:2183–2189. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jacobsen ED, Sharman JP, Oki Y, Advani RH,
Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA,
Levine P, et al: Brentuximab vedotin demonstrates objective
responses in a phase 2 study of relapsed/refractory DLBCL with
variable CD30 expression. Blood. 125:1394–1402. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Moskowitz CH, Nademanee A, Masszi T, Agura
E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A,
et al: Brentuximab vedotin as consolidation therapy after
autologous stem-cell transplantation in patients with Hodgkin's
lymphoma at risk of relapse or progression (AETHERA): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
385:1853–1862. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li J, Sim J, Leung AYH and Kwong YL:
Favorable response of relapsed/refractory gray-zone lymphoma to
brentuximab vedotin. Ann Hematol. 97:551–554. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ebisawa K, Masamoto Y, Koya J, Shimura A,
Shinozaki-Ushiku A, Toyama K, Nakazaki K and Kurokawa M: Long-term
remission by brentuximab vedotin for non-mediastinal gray zone
lymphoma refractory to autologous stem cell transplantation. Clin
Lymphoma Myeloma Leuk. 19:e602–e604. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Moskowitz CH, Walewski J, Nademanee A,
Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P,
Viviani S, et al: Five-year PFS from the AETHERA trial of
brentuximab vedotin for Hodgkin lymphoma at high risk of
progression or relapse. Blood. 132:2639–2642. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Younes A, Santoro A, Shipp M, Zinzani PL,
Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V,
Kuruvilla J, et al: Nivolumab for classical Hodgkin's lymphoma
after failure of both autologous stem-cell transplantation and
brentuximab vedotin: A multicentre, multicohort, single-arm phase 2
trial. Lancet Oncol. 17:1283–1294. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Armand P, Rodig S, Melnichenko V,
Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S,
Fogliatto L, Caballero MD, et al: Pembrolizumab in relapsed or
refractory primary mediastinal large B-cell lymphoma. J Clin Oncol.
37:3291–3299. 2019.PubMed/NCBI View Article : Google Scholar
|
